Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

February 21st 2025

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.

TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma

February 21st 2025

Christopher P. Fox, MBChB(Hons), PhD, FRCP, FRCPath, discusses the ongoing evaluation of duvelisib in nodal T-cell lymphoma.

HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging

February 21st 2025

The HyperVIEW X-ray system has received breakthrough device designation from the FDA for contrast-enhanced imaging for diagnosis of breast cancer.

RZ-001 Earns FDA Fast Track Designation in HCC

February 21st 2025

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.

Dr Harrison on Investigational JAK Inhibitor–Based Combinations in Myelofibrosis

February 21st 2025

Claire Harrison, MD, FRCP, FRCPath, discusses ongoing research with first-line JAK inhibitors for patients with myelofibrosis.

Dr Fox on the Design of the TERZO Trial of Duvelisib in R/R Nodal T-Cell Lymphoma

February 20th 2025

Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium

February 19th 2025

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma

February 18th 2025

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

February 18th 2025

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC

February 18th 2025

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma

February 18th 2025

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

February 14th 2025

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC

February 11th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma

February 11th 2025

A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.

Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC

February 11th 2025

Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.

Dr McNall-Knapp on HRQOL Outcomes With Mirdametinib in NF1-PN

February 10th 2025

Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.

Dr Colman on Outcomes With Eflornithine in Grade 3 Anaplastic Astrocytoma

February 10th 2025

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

Neoadjuvant Atezolizumab/Trastuzumab/Pertuzumab Is Effective and Safe in HER2+ Early Breast Cancer

February 10th 2025

Neoadjuvant atezolizumab plus trastuzumab, pertuzumab, and abbreviated epirubicin generated pCRs in patients with early HER2-positive breast cancer.